Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.

BACKGROUND/AIMS Cystic Fibrosis (CF) is an inherited disease associated with a variety of mutations affecting the CFTR gene. A deletion of phenylalanine 508 (F508) affects more than 70% of patients and results in unfolded proteins accumulation, originating a proteinopathy responsible for inflammation, impaired trafficking, altered metabolism, cholesterol and lipids accumulation, impaired autophagy at the cellular level. Lung inflammation has been extensively related to the accumulation of the lipotoxin ceramide. We recently proved that inhibition of ceramide synthesis by Myriocin reduces inflammation and ameliorates the defence response against pathogens infection, which is downregulated in CF. Here, we aim at demonstrating the mechanisms of Myriocin therapeutic effects in Cystic Fibrosis broncho-epithelial cells. METHODS The effect of Myriocin treatment, on F508-CFTR bronchial epithelial cell line IB3-1 cells, was studied by evaluating the expression of key proteins and genes involved in autophagy and lipid metabolism, by western blotting and real time PCR. Moreover, the amount of glycerol-phospholipids, triglycerides, and cholesterols, sphingomyelins and ceramides were measured in treated and untreated cells by LC-MS. Finally, Sptlc1 was transiently silenced and the effect on ceramide content, autophagy and transcriptional activities was evaluated as above mentioned. RESULTS We demonstrate that Myriocin tightly regulates metabolic function and cell resilience to stress. Myriocin moves a transcriptional program that activates TFEB, major lipid metabolism and autophagy regulator, and FOXOs, central lipid metabolism and anti-inflammatory/anti-oxidant regulators. The activity of these transcriptional factors is associated with the induction of PPARs nuclear receptors activity, whose targets are genes involved in lipid transport compartmentalization and oxidation. Transient silencing of SPTCL1 recapitulates the effects induced by Myriocin. CONCLUSION Cystic Fibrosis bronchial epithelia accumulate lipids, exacerbating inflammation. Myriocin administration: i) activates the transcriptions of genes involved in enhancing autophagy-mediated stress clearance; ii) reduces the content of several lipid species and, at the same time, iii) enhances mitochondrial lipid oxidation. Silencing the expression of Sptlc1 reproduces Myriocin induced autophagy and transcriptional activities, demonstrating that the inhibition of sphingolipid synthesis drives a transcriptional program aimed at addressing cell metabolism towards lipid oxidation and at exploiting autophagy mediated clearance of stress. We speculate that regulating sphingolipid de novo synthesis can relieve from chronic inflammation, improving energy supply and anti-oxidant responses, indicating an innovative therapeutic strategy for CF.

[1]  R. Paroni,et al.  An Innovative Lipidomic Workflow to Investigate the Lipid Profile in a Cystic Fibrosis Cell Line , 2020, Cells.

[2]  P. Ferroli,et al.  Long and Very-Long-Chain Ceramides Correlate with A More Aggressive Behavior in Skull Base Chordoma Patients , 2019, International journal of molecular sciences.

[3]  C. Pappone,et al.  Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury , 2019, Front. Physiol..

[4]  W. Lukiw,et al.  The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative Disorders , 2019, Molecular Neurobiology.

[5]  Tamilselvan Jayavelu,et al.  Autophagy inhibition by biotin elicits endoplasmic reticulum stress to differentially regulate adipocyte lipid and protein synthesis , 2019, Cell Stress and Chaperones.

[6]  Valerio Chiurchiù,et al.  Bioactive Lipids and Chronic Inflammation: Managing the Fire Within , 2018, Front. Immunol..

[7]  N. Vij,et al.  Cigarette Smoke Exposure Inhibits Bacterial Killing via TFEB-Mediated Autophagy Impairment and Resulting Phagocytosis Defect , 2017, Mediators of inflammation.

[8]  T. Berzin,et al.  The Clinical Implications of Fatty Pancreas: A Concise Review , 2017, Digestive Diseases and Sciences.

[9]  M. Falleni,et al.  Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  G. Oh,et al.  PPAR-α Activation Mediates Innate Host Defense through Induction of TFEB and Lipid Catabolism , 2017, The Journal of Immunology.

[11]  R. Ghidoni,et al.  2-Acetyl-5-tetrahydroxybutyl imidazole (THI) protects 661W cells against oxidative stress , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[12]  J. Olzmann,et al.  Lipid disequilibrium disrupts ER proteostasis by impairing ERAD substrate glycan trimming and dislocation , 2017, Molecular biology of the cell.

[13]  Y. C. Long,et al.  FoxO1 interacts with transcription factor EB and differentially regulates mitochondrial uncoupling proteins via autophagy in adipocytes , 2016, Cell Death Discovery.

[14]  G. Corso,et al.  Reduced absorption and enhanced synthesis of cholesterol in patients with cystic fibrosis: a preliminary study of plasma sterols , 2016, Clinical chemistry and laboratory medicine.

[15]  J. Olzmann,et al.  Endoplasmic Reticulum-Associated Degradation and Lipid Homeostasis. , 2016, Annual review of nutrition.

[16]  C. Angelini,et al.  Lipolysis and lipophagy in lipid storage myopathies , 2016, Biochimica et biophysica acta.

[17]  M. Falleni,et al.  Inhibition of ceramide de novo synthesis by myriocin produces the double effect of reducing pathological inflammation and exerting antifungal activity against A. fumigatus airways infection. , 2016, Biochimica et biophysica acta.

[18]  K. Moore,et al.  Mycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism , 2016, Nature Immunology.

[19]  T. Tatsuta,et al.  Lipid droplet–mediated ER homeostasis regulates autophagy and cell survival during starvation , 2016, The Journal of cell biology.

[20]  M. Reforgiato,et al.  Inhibition of ceramide de novo synthesis as a postischemic strategy to reduce myocardial reperfusion injury , 2016, Basic Research in Cardiology.

[21]  Christine C. Wu,et al.  VAMP-associated Proteins (VAP) as Receptors That Couple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Proteostasis with Lipid Homeostasis* , 2016, The Journal of Biological Chemistry.

[22]  Thomas A. Lagace Phosphatidylcholine: Greasing the Cholesterol Transport Machinery , 2016, Lipid insights.

[23]  Masanori Arita,et al.  MS-DIAL: Data Independent MS/MS Deconvolution for Comprehensive Metabolome Analysis , 2015, Nature Methods.

[24]  A. Ballabio,et al.  Lysosome: regulator of lipid degradation pathways , 2014, Trends in cell biology.

[25]  A. Smerieri,et al.  FOXO1 Content Is Reduced in Cystic Fibrosis and Increases with IGF-I Treatment , 2014, International journal of molecular sciences.

[26]  T. Lydic,et al.  A monophasic extraction strategy for the simultaneous lipidome analysis of polar and nonpolar retina lipids[S] , 2014, Journal of Lipid Research.

[27]  A. Bragonzi,et al.  Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis. , 2014, Biochimica et biophysica acta.

[28]  Ieda Regina Lopes Del Ciampo,et al.  Cystic Fibrosis: From Protein-Energy Malnutrition to Obesity with Dyslipidemia , 2013, Iranian journal of pediatrics.

[29]  E. Levy,et al.  Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[30]  Andrea Ballabio,et al.  Signals from the lysosome: a control centre for cellular clearance and energy metabolism , 2013, Nature Reviews Molecular Cell Biology.

[31]  A. Ballabio,et al.  TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop , 2013, Nature Cell Biology.

[32]  J. Mainz,et al.  Therapy of CF-Patients with Amitriptyline and Placebo - a Randomised, Double-Blind, Placebo-Controlled Phase IIb Multicenter, Cohort-Study , 2013, Cellular Physiology and Biochemistry.

[33]  V. Aidinis,et al.  Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. , 2013, Biochimica et biophysica acta.

[34]  P. Burgel,et al.  Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. , 2011, Journal of hepatology.

[35]  C. Carlin,et al.  Molecular pathways for intracellular cholesterol accumulation: common pathogenic mechanisms in Niemann-Pick disease Type C and cystic fibrosis. , 2011, Archives of biochemistry and biophysics.

[36]  Andrea Ballabio,et al.  TFEB regulates autophagy: An integrated coordination of cellular degradation and recycling processes , 2011, Autophagy.

[37]  Jibin Dong,et al.  Sphingomyelin synthase overexpression increases cholesterol accumulation and decreases cholesterol secretion in liver cells , 2011, Lipids in Health and Disease.

[38]  A. Ballabio,et al.  Cystic fibrosis: A disorder with defective autophagy , 2011, Autophagy.

[39]  E. Strettoi,et al.  Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa , 2010, Proceedings of the National Academy of Sciences.

[40]  A. Ballabio,et al.  Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition , 2010, Nature Cell Biology.

[41]  S. Previs,et al.  Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis , 2010, Respiratory Research.

[42]  G. Pier,et al.  Alveolar inflammation in cystic fibrosis. , 2010, Journal of Cystic Fibrosis.

[43]  E. Nash,et al.  Prevalence of dyslipidemia in adults with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[44]  T. Worgall,et al.  Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling Published, JLR Papers in Press, January 14, 2009. , 2009, Journal of Lipid Research.

[45]  R. Crystal,et al.  Influence of the cystic fibrosis transmembrane conductance regulator on expression of lipid metabolism-related genes in dendritic cells , 2009, Respiratory research.

[46]  T. Worgall Lipid metabolism in cystic fibrosis , 2009, Current opinion in clinical nutrition and metabolic care.

[47]  C. Long,et al.  Prolonged administration of a dithiol antioxidant protects against ventricular remodeling due to ischemia-reperfusion in mice. , 2008, American journal of physiology. Heart and circulatory physiology.

[48]  V. Villella,et al.  Tissue Transglutaminase Activation Modulates Inflammation in Cystic Fibrosis via PPARγ Down-Regulation1 , 2008, The Journal of Immunology.

[49]  J. Wakefield,et al.  Activation of the unfolded protein response by deltaF508 CFTR. , 2008, American journal of respiratory cell and molecular biology.

[50]  M. Weller,et al.  Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis , 2008, Nature Medicine.

[51]  S. Freedman,et al.  Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[52]  M. Wilschanski,et al.  Patterns of GI disease in adulthood associated with mutations in the CFTR gene , 2007, Gut.

[53]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[54]  N. White,et al.  Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[55]  John R. Riordan,et al.  Misassembled mutant ΔF508 CFTR in the distal secretory pathway alters cellular lipid trafficking , 2006, Journal of Cell Science.

[56]  W. Warwick,et al.  Serum fatty acid profiles in cystic fibrosis patients and their parents , 1994, Lipids.

[57]  R. Deckelbaum,et al.  Ceramide Synthesis Correlates with the Posttranscriptional Regulation of the Sterol-Regulatory Element-Binding Protein , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[58]  E. Parks,et al.  Abnormal lipid concentrations in cystic fibrosis. , 2002, The American journal of clinical nutrition.

[59]  LA Para,et al.  Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. , 1999, Diabetes.

[60]  R. Kronqvist,et al.  The rate of sphingomyelin synthesis de novo is influenced by the level of cholesterol in cultured human skin fibroblasts. , 1998, The Biochemical journal.

[61]  E. Levy,et al.  Circulating tumor necrosis factor-alpha levels and lipid abnormalities in patients with cystic fibrosis. , 1993, Pediatric research.

[62]  A. Zwinderman,et al.  Cystic fibrosis: MR imaging of the pancreas. , 1991, Radiology.

[63]  R. D. Williams,et al.  Activities of serine palmitoyltransferase (3-ketosphinganine synthase) in microsomes from different rat tissues. , 1985, Journal of lipid research.

[64]  E. Freire,et al.  Compositional domain structure in phosphatidylcholine--cholesterol and sphingomyelin--cholesterol bilayers. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.